TURNSTONE BIOLOGICS CORP. - COMMON STOCK

Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

12 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

05 Nov 2024 08:01:00 By Nasdaq GlobeNewswire

Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway

11 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

14 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

14 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

13 May 2024 16:01:26 By Nasdaq GlobeNewswire

Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference

08 May 2024 08:00:00 By Nasdaq GlobeNewswire

Turnstone Biologics Appoints William Waddill to its Board of Directors

16 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

21 Mar 2024 16:06:41 By Nasdaq GlobeNewswire

Turnstone Biologics to Participate in Upcoming Investor Conferences

21 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

20 Feb 2024 16:00:00 By Nasdaq GlobeNewswire

Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference

27 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

09 Nov 2023 20:49:42 By Nasdaq GlobeNewswire

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

03 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber

30 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

28 Sep 2023 05:00:00 By Nasdaq GlobeNewswire